Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer

ClinicalTrials.gov ID: NCT03085095

Public ClinicalTrials.gov record NCT03085095. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

HERO: A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine the efficacy and safety of relugolix 120 milligrams (mg) orally once daily for 48 weeks on maintaining serum testosterone suppression to castrate levels (\< 50 nanograms/deciliter \[ng/dL\]) in participants with androgen-sensitive advanced prostate cancer.

Study identification

NCT ID
NCT03085095
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Myovant Sciences GmbH
Industry
Enrollment
1,134 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 17, 2017
Primary completion
Oct 24, 2019
Completion
Nov 25, 2021
Last update posted
Jan 17, 2022

2017 – 2021

United States locations

U.S. sites
27
U.S. states
21
U.S. cities
27
Facility City State ZIP Site status
Tucson Tucson Arizona 85741
Orange Orange California 92868
Denver Denver Colorado 80211
Pompano Beach Pompano Beach Florida 33060
Jeffersonville Jeffersonville Indiana 47130
Des Moines Des Moines Iowa 50266
Wichita Wichita Kansas 67226
Baltimore Baltimore Maryland 21204
Troy Troy Michigan 48084
Omaha Omaha Nebraska 68130
Las Vegas Las Vegas Nevada 89135
Brick Brick New Jersey 08724
Albuquerque Albuquerque New Mexico 87109
Albany Albany New York 12208
Garden City Garden City New York 11530
Plainview Plainview New York 11803
Poughkeepsie Poughkeepsie New York 12601
Syracuse Syracuse New York 13210
Durham Durham North Carolina 27710
Greensboro Greensboro North Carolina 27403
Cincinnati Cincinnati Ohio 45212
Middleburg Heights Middleburg Heights Ohio 44130
Oklahoma City Oklahoma City Oklahoma 73104
Lancaster Lancaster Pennsylvania 17604
Myrtle Beach Myrtle Beach South Carolina 29572
Nashville Nashville Tennessee 37209
San Antonio San Antonio Texas 78258

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 135 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03085095, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 17, 2022 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03085095 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →